Sagimet Biosciences Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Sagimet Biosciences Inc. (SGMT) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $401.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-11
- Sagimet Biosciences Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$236.00K.
- Sagimet Biosciences Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $637.00K, a 81.21% decline year-over-year.
- Sagimet Biosciences Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$3.97M, a 994.82% decline year-over-year.
- Sagimet Biosciences Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $1.56M.
- Sagimet Biosciences Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $929.00K.
- Sagimet Biosciences Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$907.00K, a 855.83% decline from fiscal 2023.
- Sagimet Biosciences Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $120.00K, a 95.88% decline from fiscal 2022.
- Sagimet Biosciences Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $2.92M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$236.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $401.00K 10-Q · filed 2026-08-11 | -$3.57M derived: sum of 3 quarters · filed 2026-08-11 | -$2.01M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $637.00K 10-Q · filed 2026-05-12 | -$3.34M derived: sum of 2 quarters · filed 2026-05-12 | -$1.77M derived: sum of 3 quarters · filed 2026-05-12 | -$1.82M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | -$3.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$2.41M derived: sum of 2 quarters · filed 2026-03-11 | -$2.46M derived: sum of 3 quarters · filed 2026-08-11 | $929.00K 10-K · filed 2026-03-11 | |
| 2025-09-30 | $1.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.51M derived: sum of 2 quarters · filed 2026-08-11 | $4.90M 10-Q · filed 2025-11-13 | $5.35M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | -$51.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $3.34M 10-Q · filed 2026-08-11 | $3.78M derived: sum of 3 quarters · filed 2026-08-11 | $2.12M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $3.39M 10-Q · filed 2026-05-12 | $3.83M derived: sum of 2 quarters · filed 2026-05-12 | $2.17M derived: sum of 3 quarters · filed 2026-05-12 | $3.27M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $444.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$1.22M derived: sum of 2 quarters · filed 2026-03-11 | -$125.00K derived: sum of 3 quarters · filed 2026-03-11 | -$907.00K 10-K · filed 2026-03-11 | |
| 2024-09-30 | -$1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$569.00K derived: sum of 2 quarters · filed 2025-11-13 | -$1.35M 10-Q · filed 2025-11-13 | -$1.03M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $309.00K 10-Q · filed 2025-08-13 | $629.00K derived: sum of 3 quarters · filed 2025-08-13 | $2.02M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | -$782.00K 10-Q · filed 2025-05-08 | -$462.00K derived: sum of 2 quarters · filed 2025-05-08 | $927.00K derived: sum of 3 quarters · filed 2025-05-08 | $531.00K derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $320.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $1.71M derived: sum of 2 quarters · filed 2025-03-12 | $1.31M derived: sum of 3 quarters · filed 2025-03-12 | $120.00K 10-K · filed 2025-03-12 | |
| 2023-09-30 | $1.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $993.00K derived: sum of 2 quarters · filed 2024-11-14 | -$200.00K 10-Q · filed 2024-11-14 | -$1.21M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$396.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$1.59M 10-Q · filed 2024-08-14 | -$1.59M 10-Q · filed 2023-08-21 | -$2.59M derived: sum of 3 quarters · filed 2024-08-14 | -$1.54M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$1.19M 10-Q · filed 2024-05-15 | -$2.20M derived: sum of 2 quarters · filed 2024-05-15 | -$1.14M derived: sum of 3 quarters · filed 2024-05-15 | ||
| 2022-12-31 | -$1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $50.00K derived: sum of 2 quarters · filed 2024-03-25 | $2.92M 10-K · filed 2024-03-25 | ||
| 2022-09-30 | $1.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $3.92M 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | $2.87M 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |